In the last trading session, 8.17 million shares of the Bluebird bio Inc (NASDAQ:BLUE) were traded, and its beta was 0.83. Most recently the company’s share price was $1.02, and it changed around $0.07 or 7.03% from the last close, which brings the market valuation of the company to $196.59M. BLUE currently trades at a discount to its 52-week high of $5.53, offering almost -442.16% off that amount. The share price’s 52-week low was $0.88, which indicates that the current value has risen by an impressive 13.73% since then. We note from Bluebird bio Inc’s average daily trading volume that its 3-month average coming to 8.66 million.

Bluebird bio Inc stock received a consensus recommendation rating of Buy, based on a mean score of 2.77. If we narrow it down even further, the data shows that 1 out of 18 analysts rate the stock as a Sell; another 5 rate it as Overweight. Among the rest, 5 recommended BLUE as a Hold, whereas 7 deemed it a Buy, and 0 rated it as Underweight.

Bluebird bio Inc (NASDAQ:BLUE) trade information

Instantly BLUE has showed a green trend with a performance of 7.03% at the end of last trading. The performance over the last five days has remained in the red territory. The company’s shares are currently down -26.09% year-to-date, but still down -7.27% over the last five days. On the other hand, Bluebird bio Inc (NASDAQ:BLUE) is -27.14% down in the 30-day period.

The consensus price target as assigned by Wall Street analysts is $14.13, which translates to bulls needing to increase their stock price by 92.78% from its current value. Analyst projections state that BLUE is forecast to be at a low of $5 and a high of $25.

Bluebird bio Inc earnings are expected to increase by 10.88% in 2024, but the outlook is positive 45.80% per year for the next five years.

BLUE Dividends

Bluebird bio Inc’s next quarterly earnings report is expected to be released in May.